Updated on 2024/06/10

Information

 

写真a

 
UMAKOSHI MAKI
 
Organization
Kyushu University Hospital Department of Endocrine and Metabolic Diseases / Diabetes Mellitus Assistant Professor
Title
Assistant Professor
External link

Awards

  • 優秀演題賞

    2023.7   第41回日本骨代謝学会学術集会  

  • Clinical Investigator Award 2021

    2021.11   第12回臨床医学研究塾  

  • 第4回九州大学若手女性研究者賞(伊藤早苗賞)最優秀賞

    2021.10  

  • 優秀ポスター賞

    2020.11   第30回臨床内分泌代謝Update  

  • 第4回JES We Can九州支部賞

    2019.9   日本内分泌学会九州支部学術集会  

Papers

  • Adrenal steroid metabolites and bone status in patients with adrenal incidentalomas and hypercortisolism

    Hiroshi Nakao, Maki Yokomoto-Umakoshi, Kohta Nakatani, Hironobu Umakoshi, Masatoshi Ogata, Tazuru Fukumoto, Hiroki Kaneko, Norifusa Iwahashi, Masamichi Fujita, Tatsuki Ogasawara, Yayoi Matsuda, Ryuichi Sakamoto, Yoshihiro Izumi, Takeshi Bamba, Yoshihiro Ogawa

    eBioMedicine   104733 - 104733   2023.8

     More details

    Language:Others   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.ebiom.2023.104733

  • Coexistence of bone and vascular disturbances in patients with endogenous glucocorticoid excess. Reviewed

    Yano C, Yokomoto-Umakoshi M, Fujita M, Umakoshi H, Yano S, Iwahashi N, Katsuhara S, Kaneko H, Ogata M, Fukumoto T, Terada E, Matsuda Y, Sakamoto R, Ogawa Y

    Bone rep   2022.12

     More details

    Language:Others  

  • Impact of Cortisol on Reduction in Muscle Strength and Mass: A Mendelian Randomization Study

    Shunsuke Katsuhara, Maki Yokomoto-Umakoshi, Hironobu Umakoshi, Yayoi Matsuda, Norifusa Iwahashi, Hiroki Kaneko, Masatoshi Ogata, Tazuru Fukumoto, Eriko Terada, Ryuichi Sakamoto, Yoshihiro Ogawa

    The Journal of Clinical Endocrinology & Metabolism   2021.11

     More details

    Language:Others  

  • Protective role of DHEAS in age-related changes in bone mass and fracture risk: A Mendelian randomization study

    Maki Yokomoto-Umakoshi, Hironobu Umakoshi, Norifusa Iwahashi, Yayoi Matsuda, Hiroki Kaneko, Masatoshi Ogata, Tazuru Fukumoto, Eriko Terada, Yui Nakano, Ryuichi Sakamoto, Yoshihiro Ogawa

    The Journal of Clinical Endocrinology and Metabolism   2021.6

     More details

    Language:Others  

  • Investigating the causal effect of fibroblast growth factor 23 on osteoporosis and cardiometabolic disorders: A Mendelian randomization study Reviewed

    Maki Yokomoto-Umakoshi, Hironobu Umakoshi, Takashi Miyazawa, Masatoshi Ogata, Ryuichi Sakamoto, Yoshihiro Ogawa

    Bone   2020.11

     More details

    Language:Others  

  • Role of Deteriorated Bone Quality in the Development of Osteoporosis in Pheochromocytoma and Paraganglioma. Reviewed International journal

    Maki Yokomoto-Umakoshi, Hironobu Umakoshi, Ryuichi Sakamoto, Tazuru Fukumoto, Masatoshi Ogata, Yui Nakano, Norifusa Iwahashi, Hiroki Kaneko, Noriko Mizoguchi, Akiko Hattori, Takashi Miyazawa, Yayoi Matsuda, Hisaya Kawate, Yoshihiro Ogawa

    Bone   142   115607 - 115607   2020.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Context Pheochromocytoma (PHEO) and paraganglioma (PGL) (PHEO and PGL: PPGLs), catecholamine-producing tumors, represent an emerging cause of secondary osteoporosis. However, despite decreased bone mineral density (BMD), vertebral fracture (VF) is not associated with BMD in PPGLs. OBJECTIVE: To evaluate whether deteriorated bone quality is involved in the development of osteoporosis in PPGLs. PARTICIPANTS: Trabecular bone score (TBS), used to assess trabecular bone quality, was examined in 56 patients with PPGLs and 52 with non-functional adrenal tumors (AT). Radiograph of the spine was carried out in 35 patients with PPGLs, and TBS was analyzed in 18 patients with PPGLs at follow-up. Main outcome measure TBS and BMD at the lumbar spine in patients with PPGLs with and without VF. RESULTS: PPGLs had a lower TBS (n=56, 1.338 [1.294-1.420]) than non-functional AT (n=52, 1.394 [1.342-1.444]; p=0.033). Among those with PPGLs, patients with VF (n=14, 1.314 [1.289-1.346]) had a lower TBS than those without VF (n=21, 1.383 [1.324-1.426]; p=0.046), despite no significant difference in BMD at the lumbar spine between the two groups (p=0.501). An optimal cut-off level of TBS for diagnosing VF in PPGLs was 1.323, and its area under the curve was 0.702. The severity of catecholamine excess and maximal size of tumor were associated with decreased TBS in PPGLs patients (p=0.016 and p=0.020, respectively). Surgical resection of PPGLs improved TBS at follow-up, with 2.5% increase (p=0.007). CONCLUSIONS: This study provides evidence for the importance of deteriorated bone quality rather than decreased bone mass in the development of VF in PPGLs.

    DOI: 10.1016/j.bone.2020.115607

  • Coexistence of osteoporosis and atherosclerosis in pheochromocytoma: new insights into its long-term management Reviewed

    M. Yokomoto-Umakoshi, H. Umakoshi, M. Ogata, T. Fukumoto, Y. Matsuda, T. Miyazawa, R. Sakamoto, Y. Ogawa

    Osteoporosis International   31 ( 11 )   2151 - 2160   2020.7

     More details

    Language:Others   Publishing type:Research paper (scientific journal)  

    © 2020, International Osteoporosis Foundation and National Osteoporosis Foundation. Summary: Osteoporosis and atherosclerosis frequently coexist in patients with pheochromocytoma. The presence of osteoporosis may predict that of atherosclerosis and vice versa in patients with PHEO. These findings have implications for the long-term management of the pheochromocytoma and its potential chronic complications. Introduction: Pheochromocytoma (PHEO), a catecholamine-producing tumor, is often found incidentally, and it may be present for years before it is diagnosed. However, long-term exposure to catecholamines excess may induce chronic complications, such as osteoporosis and atherosclerosis. We aimed to evaluate concomitant osteoporosis and atherosclerosis in patients with PHEO. Methods: Fifty-one patients with PHEO and 51 patients with a non-functional adrenal tumor were compared radiographically for the prevalence of vertebral fracture (VF), a typical osteoporotic fracture, and abdominal aortic calcification (AAC). Results: In patients with PHEO, the prevalence of AAC was higher in those with VF (58&#37;) than in those without (6&#37;, p < 0.001). AAC was associated with VF after adjusting for age and sex (odds ratio, 1.53; 95&#37; confidence interval, 1.07–2.46; p = 0.003) in patients with PHEO. The degree of catecholamine excess correlated with the presence of VF and AAC (p = 0.007). The prevalence of VF was higher in patients with PHEO (37&#37;) than those with non-functional AT (12&#37;, p = 0.005), but the prevalence of AAC was comparable between the two groups (25&#37; and 19&#37;, p = 0.636). VF and AAC more frequently coexisted in patients with PHEO (22&#37;) than in those with non-functional AT (2&#37;, p = 0.003). Conclusion: This study represents the first demonstration that osteoporosis and atherosclerosis frequently coexist in patients with PHEO. The presence of osteoporosis may predict that of atherosclerosis and vice versa in patients with PHEO. These findings have implications for the long-term management of the PHEO and its potential chronic complications.

    DOI: 10.1007/s00198-020-05527-5

  • Role of Aldosterone and Potassium Levels in Sparing Confirmatory Tests in Primary Aldosteronism. Reviewed International journal

    Hironobu Umakoshi, Ryuichi Sakamoto, Yayoi Matsuda, Maki Yokomoto-Umakoshi, Hiromi Nagata, Tazuru Fukumoto, Masatoshi Ogata, Yoshihiro Ogawa

    The Journal of clinical endocrinology and metabolism   105 ( 4 )   1284 - 1289   2020.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    CONTEXT: The current clinical guidelines suggest that confirmatory tests for primary aldosteronism (PA) may be excluded in some of patients who have elevated plasma aldosterone concentration (PAC) under plasma renin suppression. However, this has low-priority evidence and is under debate in use of serum potassium. OBJECTIVE: This study aimed to investigate an appropriate setting for sparing confirmatory tests in PA. DESIGN AND SETTING: A retrospective cross-sectional study in a single referral center. PARTICIPANTS: This study included 327 patients who had hypertension under plasma renin suppression and underwent the captopril challenge test (CCT) between January 2007 and April 2019. CCT results were used to diagnose PA. MAIN OUTCOME MEASURE: Diagnostic value of PAC and serum potassium in confirmation of PA. RESULTS: Of the studied patients, 252 of 327 (77&#37;) were diagnosed with PA. All 61 patients with PAC > 30 ng/dL were diagnosed with PA. In patients with PAC between 20 and 30 ng/dL, 44 of 55 (80&#37;) were diagnosed with PA, while all 26 with PAC between 20 to 30 ng/dL who had spontaneous hypokalemia were diagnosed with PA. The proportion of unilateral PA determined by adrenal vein sampling (AVS) was higher in patients who had PAC > 30 ng/dL or those with spontaneous hypokalemia who had PAC between 20 and 30 ng/dL than those who did not meet the criteria (76&#37; vs. 17&#37;, P < .001). CONCLUSION: Confirmatory tests in PA could be spared in patients who have typical features of PA and these patients had a high probability of unilateral PA on AVS.

    DOI: 10.1210/clinem/dgz148

  • Pheochromocytoma and paraganglioma: An emerging cause of secondary osteoporosis Reviewed

    Maki Yokomoto-Umakoshi, Hironobu Umakoshi, Tazuru Fukumoto, Yayoi Matsuda, Hiromi Nagata, Masatoshi Ogata, Hisaya Kawate, Takashi Miyazawa, Ryuichi Sakamoto, Yoshihiro Ogawa

    Bone   133   115221 - 115221   2020.4

     More details

    Language:Others   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.bone.2020.115221

  • Unilateral primary aldosteronism as an independent risk factor for vertebral fracture. Reviewed International journal

    Maki Yokomoto-Umakoshi, Ryuichi Sakamoto, Hironobu Umakoshi, Yayoi Matsuda, Hiromi Nagata, Tazuru Fukumoto, Masatoshi Ogata, Yoshihiro Ogawa

    Clinical endocrinology   92 ( 3 )   206 - 213   2020.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    CONTEXT: Primary aldosteronism (PA) is known to increase vertebral fracture (VF), although the detailed mechanism remains to be elucidated. We hypothesized that the PA subtype is associated with VF. OBJECTIVE: To evaluate whether unilateral PA is associated with the prevalence of VF. DESIGN: This was a retrospective cross-sectional study in a single referral centre. PATIENTS: We identified 210 hypertensive patients whose clinical data were available for case-detection results. One hundred and fifty-two patients were diagnosed with PA using captopril challenge tests. MEASUREMENTS: We measured the prevalence of VF, according to PA subtype. RESULTS: One hundred thirteen patients with PA were subtype classified by adrenal vein sampling. Of these, 37 patients had unilateral PA, 76 patients had bilateral PA, 58 patients had non-PA; 39 patients with PA were not subtype-classified. Patients with PA had a higher prevalence of VF (29&#37;, 44/152) than those with non-PA (12&#37;, 7/58; P = .011). Moreover, unilateral PA had a higher prevalence of VF (46&#37;, 17/37) than bilateral PA (20&#37;, 15/76; P = .021). There was no significant difference in the prevalence of VF between bilateral PA and non-PA. Unilateral PA was an independent risk factor for VF after adjusting for age and sex (OR: 3.16, 95&#37; confidence interval: 1.12-8.92; P = .017). Among patients with unilateral PA, serum cortisol concentrations after 1-mg dexamethasone suppression test were higher in those with VF (1.32 ± 0.67 g/dL) than those without (0.96 ± 0.33 g/dL; P = .048). CONCLUSIONS: Unilateral PA is an independent risk factor for VF.

    DOI: 10.1111/cen.14145

  • Single-cell and spatial transcriptomics analysis of human adrenal aging. International journal

    Norifusa Iwahashi, Hironobu Umakoshi, Masamichi Fujita, Tazuru Fukumoto, Tatsuki Ogasawara, Maki Yokomoto-Umakoshi, Hiroki Kaneko, Hiroshi Nakao, Namiko Kawamura, Naohiro Uchida, Yayoi Matsuda, Ryuichi Sakamoto, Masahide Seki, Yutaka Suzuki, Kohta Nakatani, Yoshihiro Izumi, Takeshi Bamba, Yoshinao Oda, Yoshihiro Ogawa

    Molecular metabolism   101954 - 101954   2024.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVE: The human adrenal cortex comprises three functionally and structurally distinct layers that produce layer-specific steroid hormones. With aging, the human adrenal cortex undergoes functional and structural alteration or "adrenal aging", leading to the unbalanced production of steroid hormones. Given the marked species differences in adrenal biology, the underlying mechanisms of human adrenal aging have not been sufficiently studied. This study was designed to elucidate the mechanisms linking the functional and structural alterations of the human adrenal cortex. METHODS: We conducted single-cell RNA sequencing and spatial transcriptomics analysis of the aged human adrenal cortex. RESULTS: The data of this study suggest that the layer-specific alterations of multiple signaling pathways underlie the abnormal layered structure and layer-specific changes in steroidogenic cells. We also highlighted that macrophages mediate age-related adrenocortical cell inflammation and senescence. CONCLUSIONS: This study is the first detailed analysis of the aged human adrenal cortex at single-cell resolution and helps to elucidate the mechanism of human adrenal aging, thereby leading to a better understanding of the pathophysiology of age-related disorders associated with adrenal aging.

    DOI: 10.1016/j.molmet.2024.101954

  • Steroids-producing nodules: a two-layered adrenocortical nodular structure as a precursor lesion of cortisol-producing adenoma. International journal

    Tazuru Fukumoto, Hironobu Umakoshi, Norifusa Iwahashi, Tatsuki Ogasawara, Maki Yokomoto-Umakoshi, Hiroki Kaneko, Masamichi Fujita, Naohiro Uchida, Hiroshi Nakao, Namiko Kawamura, Yayoi Matsuda, Ryuichi Sakamoto, Takashi Miyazawa, Masahide Seki, Masatoshi Eto, Yoshinao Oda, Yutaka Suzuki, Seishi Ogawa, Yoshihiro Ogawa

    EBioMedicine   105087 - 105087   2024.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: The human adrenal cortex consists of three functionally and structurally distinct layers; zona glomerulosa, zona fasciculata (zF), and zona reticularis (zR), and produces adrenal steroid hormones in a layer-specific manner; aldosterone, cortisol, and adrenal androgens, respectively. Cortisol-producing adenomas (CPAs) occur mostly as a result of somatic mutations associated with the protein kinase A pathway. However, how CPAs develop after adrenocortical cells acquire genetic mutations, remains poorly understood. METHODS: We conducted integrated approaches combining the detailed histopathologic studies with genetic, RNA-sequencing, and spatially resolved transcriptome (SRT) analyses for the adrenal cortices adjacent to human adrenocortical tumours. FINDINGS: Histopathological analysis revealed an adrenocortical nodular structure that exhibits the two-layered zF- and zR-like structure. The nodular structures harbour GNAS somatic mutations, known as a driver mutation of CPAs, and confer cell proliferative and autonomous steroidogenic capacities, which we termed steroids-producing nodules (SPNs). RNA-sequencing coupled with SRT analysis suggests that the expansion of the zF-like structure contributes to the formation of CPAs, whereas the zR-like structure is characterised by a macrophage-mediated immune response. INTERPRETATION: We postulate that CPAs arise from a precursor lesion, SPNs, where two distinct cell populations might contribute differently to adrenocortical tumorigenesis. Our data also provide clues to the molecular mechanisms underlying the layered structures of human adrenocortical tissues. FUNDING: KAKENHI, The Uehara Memorial Foundation, Daiwa Securities Health Foundation, Kaibara Morikazu Medical Science Promotion Foundation, Secom Science and Technology Foundation, ONO Medical Research Foundation, and Japan Foundation for Applied Enzymology.

    DOI: 10.1016/j.ebiom.2024.105087

  • GNAS体細胞変異を有し2層構造を呈する新規副腎皮質内微小病変Steroids-producing nodule コルチゾール産生腺腫の発生機構の解明

    福元 多鶴, 馬越 洋宜, 岩橋 徳英, 小笠原 辰樹, 内田 尚宏, 兼子 大輝, 馬越 真希, 松田 やよい, 坂本 竜一, 小川 誠司, 小川 佳宏

    日本内分泌学会雑誌   99 ( 4 )   1132 - 1132   2024.1

     More details

    Language:Japanese  

  • Dectin-2 Deficiency Promotes Pro-inflammatory Cytokine Release from Macrophages and Impairs Insulin Secretion. International journal

    Masamichi Fujita, Takashi Miyazawa, Keiichiro Uchida, Naohiro Uchida, Shojiro Haji, Seiichi Yano, Norifusa Iwahashi, Tomomi Hatayama, Shunsuke Katsuhara, Shintaro Nakamura, Yukina Takeichi, Maki Yokomoto-Umakoshi, Yasutaka Miyachi, Ryuichi Sakamoto, Yoichiro Iwakura, Yoshihiro Ogawa

    Endocrinology   2023.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Pancreatic islet inflammation plays a crucial role in the etiology of type 2 diabetes (T2D). Macrophages residing in pancreatic islets have emerged as key players in islet inflammation. Macrophages express a plethora of innate immune receptors that bind to environmental and metabolic cues and integrate these signals to trigger an inflammatory response that contributes to the development of islet inflammation. One such receptor, Dectin-2, has been identified within pancreatic islets; however, its role in glucose metabolism remains largely unknown. Here we demonstrated that mice lacking Dectin-2 exhibit local inflammation within islets, along with impaired insulin secretion and β-cell dysfunction. Our findings indicate that these effects are mediated by pro-inflammatory cytokines, such as IL-1α and IL-6, which are secreted by macrophages that have acquired an inflammatory phenotype because of the loss of Dectin-2. This study provides novel insights into the mechanisms underlying the role of Dectin-2 in the development of islet inflammation.

    DOI: 10.1210/endocr/bqad181

  • Wide-scope targeted analysis of bioactive lipids in human plasma by LC/MS/MS

    Kohta Nakatani, Yoshihiro Izumi, Hironobu Umakoshi, Maki Yokomoto-Umakoshi, Tomoko Nakaji, Hiroki Kaneko, Hiroshi Nakao, Yoshihiro Ogawa, Kazutaka Ikeda, Takeshi Bamba

    Journal of Lipid Research   100492 - 100492   2023.12

     More details

    Language:Others   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.jlr.2023.100492

  • 原発性アルドステロン症におけるコルチゾール産生と椎体骨折

    藤田 政道, 馬越 真希, 馬越 洋宜, 緒方 大聖, 中谷 航太, 中尾 裕, 福元 多鶴, 兼子 大輝, 岩橋 徳英, 小笠原 辰樹, 新間 秀一, 和泉 自泰, 小川 誠司, 馬場 健史, 小川 佳宏

    日本内分泌学会雑誌   99 ( 2 )   568 - 568   2023.10

     More details

    Language:Japanese  

  • AVSに基づく原発性アルドステロン症のクラスター解析

    兼子 大輝, 馬越 洋宜, 和田 典男, 一城 貴政, 坂本 昌平, 渡邉 哲博, 石原 裕己, 田上 哲也, 福元 多鶴, 小笠原 辰樹, 岩橋 徳英, 馬越 真希, 松田 やよい, 坂本 竜一, 小川 佳宏

    日本内分泌学会雑誌   99 ( 2 )   571 - 571   2023.10

     More details

    Language:Japanese  

  • Autonomous cortisol secretionにおける骨強度の規定因子の検討

    中尾 裕, 馬越 真希, 中谷 航太, 馬越 洋宜, 緒方 大聖, 福元 多鶴, 兼子 大輝, 岩橋 徳英, 藤田 政道, 小笠原 辰樹, 松田 やよい, 坂本 竜一, 和泉 自泰, 馬場 健史, 小川 佳宏

    日本内分泌学会雑誌   99 ( 2 )   566 - 566   2023.10

     More details

    Language:Japanese  

  • ヒト副腎皮質加齢性変化のシングルセル・空間的遺伝子発現解析

    岩橋 徳英, 馬越 洋宜, 藤田 政道, 福元 多鶴, 中尾 裕, 兼子 大輝, 小笠原 辰樹, 馬越 真希, 松田 やよい, 坂本 竜一, 関 真秀, 鈴木 穣, 小川 佳宏

    日本内分泌学会雑誌   99 ( 2 )   571 - 571   2023.10

     More details

    Language:Japanese  

  • cAMP/PKA経路の活性化変異を有するコルチゾール産生副腎腺腫の表現型解析

    藤田 政道, 馬越 真希, 馬越 洋宜, 中谷 航太, 小笠原 辰樹, 福元 多鶴, 勝原 俊亮, 緒方 大聖, 岩橋 徳英, 兼子 大輝, 中尾 裕, 松田 やよい, 坂本 竜一, 宮澤 崇, 和泉 自泰, 小川 誠司, 馬場 健史, 小川 佳宏

    日本内分泌学会雑誌   99 ( 1 )   300 - 300   2023.5

     More details

    Language:Japanese  

  • Wide scope analysis of bioactive lipids, including steroids, bile acids, and polyunsaturated fatty acid metabolites, in human plasma by LC/MS/MS

    Kohta Nakatani, Yoshihiro Izumi, Hironobu Umakoshi, Maki Yokomoto-Umakoshi, Tomoko Nakaji, Hiroki Kaneko, Hiroshi Nakao, Yoshihiro Ogawa, Kazutaka Ikeda, Takeshi Bamba

    2023.4

     More details

    Language:Others  

    Abstract

    Quantitative information on blood metabolites has the potential to be utilized in medical strategies such as early disease detection and prevention. Monitoring of bioactive lipids, such as steroids, bile acids, and polyunsaturated fatty acid (PUFA) metabolites, could be a valuable indicator for health status. However, a method for simultaneous measurement of these bioactive lipids has not been reported at present. Here, we report a liquid chromatography tandem mass spectrometry (LC/MS/MS) method that can simultaneously measure more than 140 bioactive lipids, including steroids, bile acids, and PUFA metabolites, from human plasma, and a sample preparation method for these targets. Protein removal in methanol precipitation and purification operations of bioactive lipids by solid-phase extraction improved the recovery of targeted compounds in human plasma samples, demonstrating the importance of sample preparation methods in a wide range of bioactive lipid analyses. Using the developed method, we measured plasma from healthy human volunteers and confirmed the presence of bioactive lipid molecules associated with sex differences and circadian rhythms. The practical bioactive lipid analysis method developed is expected to be applied to health monitoring and disease biomarker discovery for precision medicine.

    DOI: 10.1101/2023.04.13.536679

  • 原発性アルドステロン症の病型診断における複数の機能確認検査の役割

    兼子 大輝, 馬越 洋宜, 福元 多鶴, 和田 典男, 一城 貴政, 坂本 昌平, 渡邉 哲博, 馬越 真希, 松田 やよい, 坂本 竜一, 小川 佳宏

    日本内分泌学会雑誌   98 ( 4 )   1195 - 1195   2023.2

     More details

    Language:Japanese  

  • FFPE検体を用いた副腎皮質腫瘍のwhole transcriptome profiling

    岩橋 徳英, 馬越 洋宜, 緒方 大聖, 兼子 大輝, 寺田 英李子, 馬越 真希, 松田 やよい, 坂本 竜一, 小川 佳宏

    日本内分泌学会雑誌   98 ( 4 )   1196 - 1196   2023.2

     More details

    Language:Japanese  

  • Do multiple types of confirmatory tests improve performance in predicting subtypes of primary aldosteronism? International journal

    Hiroki Kaneko, Hironobu Umakoshi, Tazuru Fukumoto, Norio Wada, Takamasa Ichijo, Shohei Sakamoto, Tetsuhiro Watanabe, Yuki Ishihara, Tetsuya Tagami, Masatoshi Ogata, Norifusa Iwahashi, Maki Yokomoto-Umakoshi, Yayoi Matsuda, Ryuichi Sakamoto, Yoshihiro Ogawa

    Clinical endocrinology   98 ( 4 )   473 - 480   2022.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVE: The clinical practice guideline for primary aldosteronism (PA) places a high value on confirmatory tests to sparing patients with false-positive results in case detection from undergoing adrenal venous sampling (AVS). However, it is unclear whether multiple types of confirmatory tests are more useful than a single type. To evaluate whether the machine-learned combination of two confirmatory tests is more useful in predicting subtypes of PA than each test alone. DESIGN: A retrospective cross-sectional study in referral centres. PATIENTS: This study included 615 patients with PA randomly assigned to the training and test data sets. The participants underwent saline infusion test (SIT) and captopril challenge test (CCT) and were subtyped by AVS (unilateral, n = 99; bilateral, n = 516). MEASUREMENTS: The area under the curve (AUC) and clinical usefulness using decision curve analysis for the subtype prediction in the test data set. RESULTS: The AUCs for the combination of SIT and CCT, SIT alone and CCT alone were 0.850, 0.813 and 0.786, respectively, with no significant differences between them. The AUC for the baseline clinical characteristics alone was 0.872, whereas the AUCs for these combined with SIT, combined with CCT and combined with both SIT and CCT were 0.868, 0.854 and 0.855, respectively, with no significant improvement in AUC. The additional clinical usefulness of the second confirmatory test was unremarkable on decision curve analysis. CONCLUSIONS: Our data suggest that patients with positive case detection undergo one confirmatory test to determine the indication for AVS.

    DOI: 10.1111/cen.14854

  • 原発性アルドステロン症の病型診断における複数の機能確認検査

    兼子 大輝, 馬越 洋宜, 福元 多鶴, 和田 典男, 一城 貴政, 坂本 昌平, 渡邉 哲博, 石原 裕己, 田上 哲也, 緒方 大聖, 岩橋 徳英, 馬越 真希, 松田 やよい, 坂本 竜一, 小川 佳宏

    日本内分泌学会雑誌   98 ( 2 )   608 - 608   2022.10

     More details

    Language:Japanese  

  • CYP11B1活性はアルドステロン産生腺腫内コルチゾール合成の規定因子である

    緒方 大聖, 馬越 洋宜, 小笠原 辰樹, 福元 多鶴, 岩橋 徳英, 兼子 大輝, 馬越 真希, 松田 やよい, 坂本 竜一, 小川 誠司, 小川 佳宏

    日本内分泌学会雑誌   98 ( 2 )   602 - 602   2022.10

     More details

    Language:Japanese  

  • FFPE検体を用いた副腎皮質腫瘍のwhole transcriptome profiling

    岩橋 徳英, 馬越 洋宜, 緒方 大聖, 福元 多鶴, 兼子 大輝, 寺田 英李子, 馬越 真希, 松田 やよい, 坂本 竜一, 小川 佳宏

    日本内分泌学会雑誌   98 ( 2 )   607 - 607   2022.10

     More details

    Language:Japanese  

  • Machine learning-based models for predicting clinical outcomes after surgery in unilateral primary aldosteronism. International journal

    Hiroki Kaneko, Hironobu Umakoshi, Masatoshi Ogata, Norio Wada, Takamasa Ichijo, Shohei Sakamoto, Tetsuhiro Watanabe, Yuki Ishihara, Tetsuya Tagami, Norifusa Iwahashi, Tazuru Fukumoto, Eriko Terada, Shunsuke Katsuhara, Maki Yokomoto-Umakoshi, Yayoi Matsuda, Ryuichi Sakamoto, Yoshihiro Ogawa

    Scientific reports   12 ( 1 )   5781 - 5781   2022.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Unilateral subtype of primary aldosteronism (PA) is a common surgically curable form of endocrine hypertension. However, more than half of the patients with PA who undergo unilateral adrenalectomy suffer from persistent hypertension, which may discourage those with PA from undergoing adrenalectomy even when appropriate. The aim of this retrospective cross-sectional study was to develop machine learning-based models for predicting postoperative hypertensive remission using preoperative predictors that are readily available in routine clinical practice. A total of 107 patients with PA who achieved complete biochemical success after adrenalectomy were included and randomly assigned to the training and test datasets. Predictive models of complete clinical success were developed using supervised machine learning algorithms. Of 107 patients, 40 achieved complete clinical success after adrenalectomy in both datasets. Six clinical features associated with complete clinical success (duration of hypertension, defined daily dose (DDD) of antihypertensive medication, plasma aldosterone concentration (PAC), sex, body mass index (BMI), and age) were selected based on predictive performance in the machine learning-based model. The predictive accuracy and area under the curve (AUC) for the developed model in the test dataset were 77.3&#37; and 0.884 (95&#37; confidence interval: 0.737-1.000), respectively. In an independent external cohort, the performance of the predictive model was found to be comparable with an accuracy of 80.4&#37; and AUC of 0.867 (95&#37; confidence interval: 0.763-0.971). The duration of hypertension, DDD of antihypertensive medication, PAC, and BMI were non-linearly related to the prediction of complete clinical success. The developed predictive model may be useful in assessing the benefit of unilateral adrenalectomy and in selecting surgical treatment and antihypertensive medication for patients with PA in clinical practice.

    DOI: 10.1038/s41598-022-09706-8

  • 機械学習を用いた原発性アルドステロン症の術後高血圧治癒予測

    兼子 大輝, 馬越 洋宜, 和田 典男, 一城 貴政, 渡邉 哲博, 緒方 大聖, 馬越 真希, 松田 やよい, 坂本 竜一, 小川 佳宏

    日本内分泌学会雑誌   97 ( 4 )   1025 - 1025   2021.12

     More details

    Language:Japanese  

  • アルドステロン産生腺腫における腫瘍内コルチゾール合成

    緒方 大聖, 馬越 洋宜, 福元 多鶴, 岩橋 徳英, 兼子 大輝, 寺田 英李子, 馬越 真希, 松田 やよい, 坂本 竜一, 小川 佳宏

    日本内分泌学会雑誌   97 ( 4 )   1042 - 1042   2021.12

     More details

    Language:Japanese  

  • アルドステロン産生腺腫における腫瘍内コルチゾール合成

    緒方 大聖, 馬越 洋宜, 福元 多鶴, 岩橋 徳英, 兼子 大輝, 寺田 英李子, 馬越 真希, 松田 やよい, 坂本 竜一, 小川 佳宏

    日本内分泌学会雑誌   97 ( 4 )   1042 - 1042   2021.12

     More details

    Language:Japanese  

  • Impact of Cortisol on Reduction in Muscle Strength and Mass: A Mendelian Randomization Study. Reviewed International journal

    Shunsuke Katsuhara, Maki Yokomoto-Umakoshi, Hironobu Umakoshi, Yayoi Matsuda, Norifusa Iwahashi, Hiroki Kaneko, Masatoshi Ogata, Tazuru Fukumoto, Eriko Terada, Ryuichi Sakamoto, Yoshihiro Ogawa

    The Journal of clinical endocrinology and metabolism   107 ( 4 )   e1477-e1487   2021.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: Prolonged exposure to pathological cortisol, as in Cushing's syndrome causes various age-related disorders including sarcopenia. However, it is unclear whether mild cortisol excess, for example, accelerates sarcopenia due to aging or chronic stress. We performed a Mendelian randomization (MR) analysis to assess whether cortisol was causally associated with muscle strength and mass. METHODS: Three single nucleotide polymorphisms associated with plasma cortisol concentrations in the CORtisol NETwork consortium (n = 12,597) were used as instrumental variables. Summary statistics with traits of interest were obtained from relevant genome-wide association studies. For the primary analysis, we used the fixed-effects inverse-variance weighted analysis accounting for genetic correlations between variants. RESULTS: One standard deviation (SD) increase in cortisol was associated with SD reduction in grip strength (estimate, -0.032; 95&#37; confidence interval [CI] -0.044 ~ -0.020; P = 3e-04), whole-body lean mass (estimate, -0.032; 95&#37;CI, -0.046 ~ -0.017; P = 0.004), and appendicular lean mass (estimate, -0.031; 95&#37;CI, -0.049 ~ -0.012; P = 0.001). The results were supported by the weighted-median analysis, with no evidence of pleiotropy in the MR-Egger analysis. The association of cortisol with grip strength and lean mass was observed in women but not in men. The association was attenuated after adjusting for fasting glucose in the multivariable MR analysis, which was the top mediator for the association in the MR-Bayesian model averaging analysis. CONCLUSION: This MR study provides evidence for the association of cortisol with reduced muscle strength and mass, suggesting the impact of cortisol on the development of sarcopenia.

    DOI: 10.1210/clinem/dgab862

  • 機械学習を用いた原発性アルドステロン症の術後高血圧治癒予測

    兼子 大輝, 馬越 洋宜, 緒方 大聖, 和田 典男, 一城 貴政, 坂本 昌平, 渡邉 哲博, 馬越 真希, 松田 やよい, 坂本 竜一, 小川 佳宏

    日本内分泌学会雑誌   97 ( 2 )   538 - 538   2021.10

     More details

    Language:Japanese  

  • コルチゾールのサルコペニアへの影響 メンデルランダム化研究

    勝原 俊亮, 馬越 真希, 馬越 洋宜, 松田 やよい, 岩橋 徳英, 兼子 大輝, 緒方 大聖, 福元 多鶴, 寺田 英李子, 坂本 竜一, 小川 佳宏

    日本内分泌学会雑誌   97 ( 2 )   557 - 557   2021.10

     More details

    Language:Japanese  

  • Protective Role of DHEAS in Age-related Changes in Bone Mass and Fracture Risk: A Mendelian Randomization Study. International journal

    Maki Yokomoto-Umakoshi, Hironobu Umakoshi, Norifusa Iwahashi, Yayoi Matsuda, Hiroki Kaneko, Masatoshi Ogata, Tazuru Fukumoto, Eriko Terada, Yui Nakano, Ryuichi Sakamoto, Yoshihiro Ogawa

    The Journal of clinical endocrinology and metabolism   2021.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: Dehydroepiandrosterone sulfate (DHEAS) from the adrenal cortex substantially decreases with age, which may accelerate osteoporosis. However, the association of DHEAS with bone mineral density (BMD) and fracture is inconclusive. We conducted a Mendelian randomization (MR) analysis to investigate the role of DHEAS in age-related changes in BMD and fracture risk. METHODS: Single nucleotide polymorphisms (SNPs) associated with serum DHEAS concentrations were used as instrumental variables (4 SNPs for main analysis; 4 SNPs for men and 5 SNPs for women in sex-related analysis). Summary statistics were obtained from relevant genome-wide association studies. RESULTS: A log-transformed unit (μmol/L) increase in serum DHEAS concentrations was associated with SD increase in estimated BMD at the heel (estimate, 0.120; 95&#37; confidence interval [CI], 0.081-0.158; P = 9 × 10 -10), and decreased fracture (odds ratio [OR], 0.989; 95&#37;CI, 0.981-0.996; P = 0.005), consistent with dual-energy X-ray absorptiometry-derived BMD at the femoral neck and lumbar spine. Their associations remained even after adjusting for height, body mass index, testosterone, estradiol, sex hormone-binding globulin, and IGF-1. The association of DHEAS with fracture remained after adjusting for falls, grip strength, and physical activity but was attenuated after adjusting for BMD. The MR-Baysian model averaging analysis showed BMD was the top mediating factor for association of DHEAS with fracture. The association between DHEAS and BMD was observed in men but not in women. CONCLUSION: DHEAS was associated with increased BMD and decreased fracture. DHEAS may play a protective role in decreasing fracture risk, mainly by increasing bone mass.

    DOI: 10.1210/clinem/dgab459

  • Protective Role of DHEAS in Age-related Changes in Bone Mass and Fracture Risk. International journal

    Maki Yokomoto-Umakoshi, Hironobu Umakoshi, Norifusa Iwahashi, Yayoi Matsuda, Hiroki Kaneko, Masatoshi Ogata, Tazuru Fukumoto, Eriko Terada, Yui Nakano, Ryuichi Sakamoto, Yoshihiro Ogawa

    The Journal of clinical endocrinology and metabolism   106 ( 11 )   e4580-e4592   2021.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: Dehydroepiandrosterone sulfate (DHEAS) from the adrenal cortex substantially decreases with age, which may accelerate osteoporosis. However, the association of DHEAS with bone mineral density (BMD) and fracture is inconclusive. We conducted a Mendelian randomization (MR) analysis to investigate the role of DHEAS in age-related changes in BMD and fracture risk. METHODS: Single nucleotide polymorphisms (SNPs) associated with serum DHEAS concentrations were used as instrumental variables (4 SNPs for main analysis; 4 SNPs for men and 5 SNPs for women in sex-related analysis). Summary statistics were obtained from relevant genome-wide association studies. RESULTS: A log-transformed unit (µmol/L) increase in serum DHEAS concentrations was associated with an SD increase in estimated BMD at the heel (estimate, 0.120; 95&#37; CI, 0.081-0.158; P = 9 × 10-10), and decreased fracture (odds ratio, 0.989; 95&#37; CI, 0.981-0.996; P = 0.005), consistent with dual-energy X-ray absorptiometry-derived BMD at the femoral neck and lumbar spine. Their associations remained even after adjusting for height, body mass index, testosterone, estradiol, sex hormone-binding globulin, and insulin-like growth factor 1. The association of DHEAS with fracture remained after adjusting for falls, grip strength, and physical activity but was attenuated after adjusting for BMD. The MR-Bayesian model averaging analysis showed BMD was the top mediating factor for association of DHEAS with fracture. The association between DHEAS and BMD was observed in men but not in women. CONCLUSION: DHEAS was associated with increased BMD and decreased fracture. DHEAS may play a protective role in decreasing fracture risk, mainly by increasing bone mass.

    DOI: 10.1210/clinem/dgab459

  • Machine learning based models for prediction of subtype diagnosis of primary aldosteronism using blood test. International journal

    Hiroki Kaneko, Hironobu Umakoshi, Masatoshi Ogata, Norio Wada, Norifusa Iwahashi, Tazuru Fukumoto, Maki Yokomoto-Umakoshi, Yui Nakano, Yayoi Matsuda, Takashi Miyazawa, Ryuichi Sakamoto, Yoshihiro Ogawa

    Scientific reports   11 ( 1 )   9140 - 9140   2021.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Primary aldosteronism (PA) is associated with an increased risk of cardiometabolic diseases, especially in unilateral subtype. Despite its high prevalence, the case detection rate of PA is limited, partly because of no clinical models available in general practice to identify patients highly suspicious of unilateral subtype of PA, who should be referred to specialized centers. The aim of this retrospective cross-sectional study was to develop a predictive model for subtype diagnosis of PA based on machine learning methods using clinical data available in general practice. Overall, 91 patients with unilateral and 138 patients with bilateral PA were randomly assigned to the training and test cohorts. Four supervised machine learning classifiers; logistic regression, support vector machines, random forests (RF), and gradient boosting decision trees, were used to develop predictive models from 21 clinical variables. The accuracy and the area under the receiver operating characteristic curve (AUC) for predicting of subtype diagnosis of PA in the test cohort were compared among the optimized classifiers. Of the four classifiers, the accuracy and AUC were highest in RF, with 95.7&#37; and 0.990, respectively. Serum potassium, plasma aldosterone, and serum sodium levels were highlighted as important variables in this model. For feature-selected RF with the three variables, the accuracy and AUC were 89.1&#37; and 0.950, respectively. With an independent external PA cohort, we confirmed a similar accuracy for feature-selected RF (accuracy: 85.1&#37;). Machine learning models developed using blood test can help predict subtype diagnosis of PA in general practice.

    DOI: 10.1038/s41598-021-88712-8

  • メタボロミクスに基づく副腎皮質腫瘍の代謝特性の解明と医学応用

    馬越 洋宜, 瀬戸山 大樹, 坂本 竜一, 松田 やよい, 馬越 真希, 緒方 大聖, 小川 佳宏

    大和証券ヘルス財団研究業績集   ( 44 )   105 - 108   2021.3

     More details

    Language:Japanese  

    副腎皮質腫瘍を対象として、液体クロマトグラフィータンデム質量分析(LC/MS/MS)によるメタボロミクスを基盤とした腫瘍組織の統合解析から、副腎皮質腫瘍における代謝特性の多様性の成因を明らかにすることを目的とした。アルドステロン産生腫瘍、顕性コルチゾール産生腫瘍、不顕性コルチゾール産生腫瘍、非副腎皮質腫瘍を対象として、LC/MS/MSを用いて組織中のアルドステロン、コルチゾールの定量を行った。アルドステロンについては、アルドステロン産生腫瘍においてのみ有意な上昇がみられたが、コルチゾールにおいては、興味深いことにアルドステロン産生腫瘍は不顕性コルチゾール産生腫瘍と同定度のコルチゾール過剰分泌がみられた。アルドステロン産生腫瘍における、腫瘍内コルチゾール合成の局在を評価する目的で、代謝産物の可視化法として、最新技術であるイメージング質量顕微鏡を用いた解析を行った。免疫組織学染色のコルチゾール合成酵素(CYP11B1)の局在と一致して、コルチゾール合成が腫瘍内で均一的に行われることを同定した。アルドステロン産生腫瘍およびコルチゾール分泌が緩徐である、不顕性コルチゾール産生腫瘍を対象として、RNA-seqを施行した。315遺伝子に発現変動が確認され、予想通りAPAにおいてアルドステロン合成に関連するパスウェイがエンリッチされた。一方で、steroid metabolic processパスウェイ(27遺伝子)もエンリッチされていたが、コルチゾール合成に関連する遺伝子発現は両腫瘍において差異は検出されなかった。

  • 機械学習を用いた一般血液検査による原発性アルドステロン症のサブタイプ診断予測

    兼子 大輝, 馬越 洋宜, 緒方 大聖, 和田 典男, 福元 多鶴, 馬越 真希, 松田 やよい, 宮澤 崇, 坂本 竜一, 小川 佳宏

    日本内科学会雑誌   110 ( Suppl. )   144 - 144   2021.2

     More details

    Language:Japanese  

  • 原発性アルドステロン症の片側性サブタイプ診断における左副腎静脈内アルドステロン濃度勾配の有用性

    緒方 大聖, 馬越 洋宜, 福元 多鶴, 松田 やよい, 馬越 真希, 永田 宙生, 和田 典男, 宮澤 崇, 坂本 竜一, 小川 佳宏

    日本内科学会雑誌   110 ( Suppl. )   144 - 144   2021.2

     More details

    Language:Japanese  

  • 原発性アルドステロン症の診断における機能検査結果乖離例の検討

    福元 多鶴, 馬越 洋宜, 緒方 大聖, 馬越 真希, 松田 やよい, 和田 典男, 坂本 竜一, 小川 佳宏

    日本内科学会雑誌   110 ( Suppl. )   144 - 144   2021.2

     More details

    Language:Japanese  

  • 原発性アルドステロン症の片側性サブタイプ診断における左副腎静脈内アルドステロン濃度勾配の有用性

    緒方 大聖, 馬越 洋宜, 福元 多鶴, 松田 やよい, 馬越 真希, 永田 宙生, 和田 典男, 宮澤 崇, 坂本 竜一, 小川 佳宏

    日本内科学会雑誌   110 ( Suppl. )   144 - 144   2021.2

     More details

    Language:Japanese  

  • 機械学習を用いた一般血液検査による原発性アルドステロン症のサブタイプ診断予測

    兼子 大輝, 馬越 洋宜, 緒方 大聖, 和田 典男, 福元 多鶴, 馬越 真希, 松田 やよい, 宮澤 崇, 坂本 竜一, 小川 佳宏

    日本内科学会雑誌   110 ( Suppl. )   144 - 144   2021.2

     More details

    Language:Japanese  

  • 原発性アルドステロン症の診断における機能検査結果乖離例の検討

    福元 多鶴, 馬越 洋宜, 緒方 大聖, 馬越 真希, 松田 やよい, 元谷 実里, 永田 宙生, 中野 結衣, 岩橋 徳英, 兼子 大樹, 和田 典男, 宮澤 崇, 坂本 竜一, 小川 佳宏

    日本内分泌学会雑誌   96 ( 3 )   869 - 869   2021.1

     More details

    Language:Japanese  

  • 副腎静脈サンプリングにおける左副腎静脈内アルドステロン濃度勾配の意義

    緒方 大聖, 馬越 洋宜, 福元 多鶴, 松田 やよい, 馬越 真希, 永田 宙生, 和田 典男, 宮澤 崇, 坂本 竜一, 小川 佳宏

    日本内分泌学会雑誌   96 ( 3 )   852 - 852   2021.1

     More details

    Language:Japanese  

  • 原発性アルドステロン症の診断における機能検査結果乖離例の検討

    福元 多鶴, 馬越 洋宜, 緒方 大聖, 馬越 真希, 松田 やよい, 元谷 実里, 永田 宙生, 中野 結衣, 岩橋 徳英, 兼子 大樹, 和田 典男, 宮澤 崇, 坂本 竜一, 小川 佳宏

    日本内分泌学会雑誌   96 ( 3 )   869 - 869   2021.1

     More details

    Language:Japanese  

  • Significance of Discordant Results between Confirmatory Tests in Diagnosis of Primary Aldosteronism International journal

    Tazuru Fukumoto, Hironobu Umakoshi, Masatoshi Ogata, Maki Yokomoto-Umakoshi, Yayoi Matsuda, Misato Motoya, Hiromi Nagata, Yui Nakano, Norifusa Iwahashi, Hiroki Kaneko, Norio Wada, Takashi Miyazawa, Ryuichi Sakamoto, Yoshihiro Ogawa

    The Journal of Clinical Endocrinology & Metabolism   106 ( 2 )   e866-e874   2020.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    <title>Abstract</title>
    <sec>
    <title>Context</title>
    Current clinical guidelines recommend confirmation of positive result in at least one confirmatory test in the diagnosis of primary aldosteronism (PA). Clinical implication of multiple confirmatory tests has not been established, especially when patients show discordant results.


    </sec>
    <sec>
    <title>Objective</title>
    The aim of the present study was to explore the role of two confirmatory tests in subtype diagnosis of PA.


    </sec>
    <sec>
    <title>Design</title>
    Retrospective cross-sectional study.


    </sec>
    <sec>
    <title>Setting</title>
    The study was conducted at two referral centers.


    </sec>
    <sec>
    <title>Participants and Method</title>
    We identified 360 hypertensive patients who underwent both captopril challenge test (CCT) and saline infusion test (SIT) and exhibited at least one positive result. Among them, we studied 193 patients with PA whose data were available for subtype diagnosis based on adrenal vein sampling (AVS).


    </sec>
    <sec>
    <title>Main Outcome Measure</title>
    The prevalence of bilateral subtype on AVS according to the results of the confirmatory tests.


    </sec>
    <sec>
    <title>Results</title>
    Of patients studied, 127 were positive for both CCT and SIT (double-positive), while 66 were positive for either CCT or SIT (single-positive) (n = 34 and n = 32, respectively). Altogether, 135 were diagnosed with bilateral subtype on AVS. The single-positive patients had milder clinical features of PA than the double-positive patients. The prevalence of bilateral subtype on AVS was significantly higher in the single-positive patients than in the double-positive patients. (63/66 [95.5&#37;] vs. 72/127 [56.7&#37;], P &amp;lt; 0.01). Several clinical parameters were different between CCT single-positive and SIT single-positive patients.


    </sec>
    <sec>
    <title>Conclusion</title>
    Patients with discordant results between CCT and SIT have a high probability of bilateral subtype of PA on AVS.


    </sec>

    DOI: 10.1210/clinem/dgaa812

  • 「副腎関連骨粗鬆症」の概念と病態

    馬越 真希, 馬越 洋宜, 緒方 大聖, 福元 多鶴, 松田 やよい, 中野 結衣, 岩橋 徳英, 兼子 大輝, 宮澤 崇, 坂本 竜一, 小川 佳宏

    日本骨粗鬆症学会雑誌   6 ( Suppl.1 )   310 - 310   2020.9

     More details

    Language:Japanese  

  • Significance of aldosterone gradient within left adrenal vein in diagnosing unilateral subtype of primary aldosteronism

    Masatoshi Ogata, Hironobu Umakoshi, Tazuru Fukumoto, Yayoi Matsuda, Maki Yokomoto‐Umakoshi, Hiromi Nagata, Norio Wada, Takashi Miyazawa, Ryuichi Sakamoto, Yoshihiro Ogawa

    Clinical Endocrinology   2020.9

     More details

    Language:Others   Publishing type:Research paper (scientific journal)  

    © 2020 John Wiley & Sons Ltd Context: The success rate of cannulation of the right adrenal vein is limited. The aldosterone gradient within the same adrenal vein branch is specific for aldosterone-producing adenoma. Objective: This study was performed to investigate whether the absolute aldosterone gradient within the left adrenal vein (left-AV absolute aldosterone gradient) indicates unilateral excess aldosterone. Design and setting: A retrospective cross-sectional study in a single referral centre. Patients and methods: In total, 123 consecutive patients with primary aldosteronism who had successful adrenal vein sampling (AVS) data were examined. The left-AV absolute aldosterone gradient was considered significant when a gradient of >4:1 in the aldosterone-to-cortisol ratio between the common trunk vein and central vein was found. Main outcome measure: The prevalence of the unilateral subtype in patients with a significant left-AV absolute aldosterone gradient. Results: The prevalence of the unilateral subtype was higher in patients with than without a significant left-AV absolute aldosterone gradient (88.2&#37; [15/17] vs 21.7&#37; [23/106], P <.001). Of 60 patients with spontaneous hypokalemia, left unilateral disease on computed tomography, or both, a significant left-AV absolute aldosterone gradient was present only in patients with the unilateral subtype on AVS (42.9&#37; [15/35]), but not in those with the bilateral subtype (0.0&#37; [0/25]). These data were validated in an external cohort. Conclusion: The presence of a significant left-AV absolute aldosterone gradient can be used to diagnose the left unilateral subtype of primary aldosteronism on AVS in patients with spontaneous hypokalemia, left unilateral disease on computed tomography or both.

    DOI: 10.1111/cen.14320

  • 褐色細胞腫と骨粗鬆症 椎体骨折リスクと腫瘍摘出前後の骨密度の検討

    馬越 真希, 馬越 洋宜, 福元 多鶴, 松田 やよい, 永田 宙生, 緒方 大聖, 元谷 実里, 中野 結衣, 河手 久弥, 宮澤 崇, 坂本 竜一, 小川 佳宏

    日本内分泌学会雑誌   96 ( 1 )   354 - 354   2020.8

     More details

    Language:Japanese  

  • 原発性アルドステロン症診断に2種類の機能確認検査を施行する意義

    福元 多鶴, 馬越 洋宜, 緒方 大聖, 馬越 真希, 永田 宙生, 松田 やよい, 坂本 竜一, 小川 佳宏

    日本内分泌学会雑誌   96 ( 1 )   317 - 317   2020.8

     More details

    Language:Japanese  

  • 原発性アルドステロン症診断に2種類の機能確認検査を施行する意義

    福元 多鶴, 馬越 洋宜, 緒方 大聖, 馬越 真希, 永田 宙生, 松田 やよい, 坂本 竜一, 小川 佳宏

    日本内分泌学会雑誌   96 ( 1 )   317 - 317   2020.8

     More details

    Language:Japanese  

  • 褐色細胞腫と骨粗鬆症 椎体骨折リスクと腫瘍摘出前後の骨密度の検討

    馬越 真希, 馬越 洋宜, 福元 多鶴, 松田 やよい, 永田 宙生, 緒方 大聖, 元谷 実里, 中野 結衣, 河手 久弥, 宮澤 崇, 坂本 竜一, 小川 佳宏

    日本内分泌学会雑誌   96 ( 1 )   354 - 354   2020.8

     More details

    Language:Japanese  

  • アルドステロン濃度と血清カリウム値に基づく原発性アルドステロン症診断の簡素化

    松田 やよい, 馬越 洋宜, 坂本 竜一, 緒方 大聖, 馬越 真希, 永田 宙生, 福元 多鶴, 小川 佳宏

    日本内科学会雑誌   109 ( Suppl. )   166 - 166   2020.2

     More details

    Language:Japanese  

  • アルドステロン濃度と血清カリウム値に基づく原発性アルドステロン症診断の簡素化

    松田 やよい, 馬越 洋宜, 坂本 竜一, 緒方 大聖, 馬越 真希, 永田 宙生, 福元 多鶴, 小川 佳宏

    日本内科学会雑誌   109 ( Suppl. )   166 - 166   2020.2

     More details

    Language:Japanese  

  • 原発性アルドステロン症における椎体骨折リスク因子の解明

    馬越 真希, 馬越 洋宜, 坂本 竜一, 松田 やよい, 永田 宙生, 福元 多鶴, 緒方 大聖, 小川 佳宏

    日本内分泌学会雑誌   95 ( 2 )   796 - 796   2019.10

     More details

    Language:Japanese  

  • アルドステロン濃度とカリウム所見に基づくPA診断手順の簡素化

    緒方 大聖, 馬越 洋宜, 坂本 竜一, 松田 やよい, 馬越 真希, 永田 宙生, 福元 多鶴, 小川 佳宏

    日本内分泌学会雑誌   95 ( 2 )   738 - 738   2019.10

     More details

    Language:Japanese  

  • Seasonal Variation in Severe Glucose-lowering Drug-induced Hypoglycemia in Patients with Type 2 Diabetes.

    Mayu Minamoto-Higashioka, Ryoichi Kawamura, Hironobu Umakoshi, Maki Yokomoto-Umakoshi, Daisuke Utsunomiya, Haruhiko Osawa, Shiori Kondo

    Internal medicine (Tokyo, Japan)   58 ( 8 )   1067 - 1072   2019.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Objective Glucose-lowering drug-induced hypoglycemia is a serious complication and there have been a few reports of seasonal variations in hypoglycemia in patients with type 2 diabetes. The aim of the present study was to examine the association between severe drug-induced hypoglycemia and seasonal variations, and to elucidate the contributing factors. Methods This retrospective, single center clinical study, analyzed the cases of 125 patients who required emergency hospitalization for severe drug-induced hypoglycemia between January 1, 2001 and December 31, 2014. The period from November to April was defined as the cold season. Results Severe hypoglycemia occurred more often in the cold season than in the warm season. In the cold season, 62 of 9,981 (0.6&#37;) emergency department visits involved patients who required hospitalization for drug-induced hypoglycemia. In contrast, in the warm season, 27 of 8,649 (0.3&#37;) visits involved patients who required hospitalization for drug-induced hypoglycemia (p=0.002). The proportion of patients treated with sulfonylurea (SU) in the cold season was higher than that in the warm season. Even the use of low-dose SU caused hypoglycemia in the cold season. In the SU-treated group, the proportion of patients with white blood cell and/or C-reactive protein elevation was higher in the cold season than in the warm season (p=0.04). Conclusion Severe glucose-lowering drug-induced hypoglycemia occured more frequently in the cold season than in the warm season, and was associated with an inflammatory state in patients treated with SU.

    DOI: 10.2169/internalmedicine.1360-18

  • 頭頸部放射線照射後の甲状腺機能低下症による粘液水腫性昏睡の一例

    濱中 佳歩[廣嶋], 立木 美香, 兼子 大輝, 石原 裕己, 天野 綾, 横本 真希, 馬越 洋宜, 日下部 徹, 浅原 哲子, 成瀬 光栄, 島津 章, 田上 哲也

    日本内分泌学会雑誌   94 ( 4 )   1252 - 1252   2018.12

     More details

    Language:Japanese  

  • 急性心不全を契機に診断された多発性パラガングリオーマの1例

    成瀬 光栄, 笹井 有美子, 立木 美香, 兼子 大輝, 濱中 佳歩, 横本 真希, 小笠原 辰樹, 馬越 洋宜, 田上 哲也, 島津 章, 白神 幸太郎, 奥野 博, 安里 亮, 森吉 弘毅, 木村 伯子

    日本内分泌学会雑誌   94 ( 4 )   1683 - 1683   2018.12

     More details

    Language:Japanese  

  • 当院における褐色細胞腫の臨床的特徴

    立木 美香, 横本 真希, 馬越 洋宣, 兼子 大輝, 廣嶋 佳歩, 石原 裕己, 天野 綾, 田上 哲也, 島津 章, 成瀬 光栄

    国立病院総合医学会講演抄録集   72回   529 - 529   2018.11

     More details

    Language:Japanese  

  • 左副腎腫瘍と下垂体macroadenomaを併発した一例

    濱中 佳歩[廣嶋], 小林 真以子[垣田], 立木 美香, 兼子 大輝, 石原 裕己, 天野 綾, 横本 真希, 馬越 洋宜, 日下部 徹, 浅原 哲子, 田上 哲也, 成瀬 光栄, 内田 稔大, 島津 章

    日本内分泌学会雑誌   94 ( 2 )   715 - 715   2018.9

     More details

    Language:Japanese  

  • 褐色細胞腫・パラガングリオーマ診療ガイドライン2018

    成瀬 光栄, 方波見 卓行, 田辺 晶代, 織内 昇, 木村 伯子, 絹谷 清剛, 柴田 洋孝, 高橋 克敏, 滝澤 奈恵, 竹越 一博, 立木 美香, 難波 多挙, 橋本 重厚, 松田 公志, 横本 真希, 今井 常夫, 大月 道夫, 奥野 博, 桑鶴 良平, 曽根 正勝, 田村 功一, 西本 紘嗣郎, 長谷川 奉延, 日村 好宏, 吉永 恵一郎, 楽木 宏実, 島本 和明, 新保 卓郎, 平田 結喜緒, 宮崎 康, 一般社団法人日本内分泌学会, 日本内分泌学会「悪性褐色細胞腫の実態調査と診療指針の作成」委員会, 特定非営利活動法人日本高血圧学会, 日本内分泌外科学会, 日本妊娠高血圧学会, 厚生労働省科学研究費補助金難治性疾患等政策研究事業副腎ホルモン産生異常に関する調査研究班, 国際医療研究開発費「難治性副腎腫瘍の疾患レジストリーと診療実態に関する検討」研究班, 日本医療研究開発機構研究費(難治性疾患実用化研究事業)「難治性副腎疾患の診療に直結するエビデンス創出」研究班

    日本内分泌学会雑誌   94 ( Suppl. )   i - 87   2018.8

     More details

    Language:Japanese  

  • Correlation Between Lateralization Index of Adrenal Venous Sampling and Standardized Outcome in Primary Aldosteronism. Reviewed International journal

    Hironobu Umakoshi, Mika Tsuiki, Maki Yokomoto-Umakoshi, Yoshiyu Takeda, Yoneda Takashi, Isao Kurihara, Hiroshi Itoh, Takuyuki Katabami, Takamasa Ichijo, Norio Wada, Yui Shibayama, Takanobu Yoshimoto, Kenji Ashida, Yoshihiro Ogawa, Junji Kawashima, Masakatsu Sone, Nobuya Inagaki, Katsutoshi Takahashi, Minemori Watanabe, Yuichi Matsuda, Hiroki Kobayashi, Hirotaka Shibata, Kohei Kamemura, Michio Otsuki, Yuichi Fujii, Koichi Yamamto, Atsushi Ogo, Shintaro Okamura, Shozo Miyauchi, Tomikazu Fukuoka, Shoichiro Izawa, Toshihiko Yanase, Shigeatsu Hashimoto, Masanobu Yamada, Yuichiro Yoshikawa, Tatsuya Kai, Tomoko Suzuki, Takashi Kawamura, Mitsuhide Naruse

    Journal of the Endocrine Society   2 ( 8 )   893 - 902   2018.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Objectives: The aim of this study was to investigate the impact of adrenal venous sampling (AVS) lateralization cutoffs on surgical outcomes. Patients and Methods: Cosyntropin-stimulated AVS was used to guide surgical management of 377 patients with primary aldosteronism (PA) who were evaluated 6 months after surgery. Main Outcome Measures: The proportion of patients that achieved clinical benefit and complete biochemical success based on the AVS aldosterone lateralization index (LI) was determined. Results: Clinical benefit was achieved in 29 of 47 patients with an LI between 2 and 4, in 66 of 101 with an LI between 4 and 10, and in 158 of 203 with an LI > 10 (P < 0.01 for trend). Complete biochemical success was achieved in 27 of 42 with an LI between 2 and 4, in 60 of 76 with an LI between 4 and 10, and in 127 of 155 with an LI > 10 (P = 0.024 for trend). After adjustment for confounders and using those patients with an LI between 2 and 4 as a reference, a clinical benefit was associated only with those with an LI > 10 (OR, 2.30; 95&#37; CI, 1.03 to 5.16), whereas complete biochemical success was associated with those with an LI between 4 and 10 (OR, 2.83; 95&#37; CI, 1.14 to 7.01) or LI > 10 (OR, 3.55; 95&#37; CI, 1.47 to 8.55). Conclusions: Difference of clinical outcome was relatively small when strict LI diagnostic threshold was used; biochemical cure was sufficiently achieved when an LI > 4 was used. Our study by standardized outcome measures validated that an LI > 4 may be appropriate for determining unilateral disease in PA.

    DOI: 10.1210/js.2018-00055

  • 褐色細胞腫の診療におけるクリニカルポイント

    立木 美香, 馬越 洋宜, 横本 真希, 兼子 大輝, 廣嶋 佳歩, 笹井 有美子, 田上 哲也, 島津 章, 成瀬 光栄

    日本内分泌学会雑誌   94 ( 1 )   239 - 239   2018.4

     More details

    Language:Japanese  

  • TRAb値とTSAb値に乖離を認めた高齢男性の甲状腺眼症の1例

    濱中 佳歩[廣嶋], 笹井 有美子, 兼子 大輝, 横本 真希, 馬越 洋宜, 立木 美香, 浅原 哲子, 成瀬 光栄, 島津 章, 濱 祥代, 田上 哲也

    日本内分泌学会雑誌   94 ( 1 )   373 - 373   2018.4

     More details

    Language:Japanese  

  • 急性心不全を契機に診断された心臓パラガングリオーマの1例

    笹井 有美子, 兼子 大輝, 濱中 佳歩, 横本 真希, 小笠原 辰樹, 垣田 麻衣子, 馬越 洋宜, 立木 美香, 日下部 徹, 浅原 哲子, 田上 哲也, 島津 章, 白神 幸太郎, 相川 幸生, 玉那覇 民子, 岡田 厚, 成瀬 光栄

    日本内分泌学会雑誌   94 ( 1 )   317 - 317   2018.4

     More details

    Language:Japanese  

  • 治癒切除が困難な左心房腫瘍を伴う多発性傍神経節腫瘍の1例

    笹井 有美子, 兼子 大輝, 廣嶋 佳歩, 横本 真希, 馬越 洋宜, 立木 美香, 日下部 徹, 浅原 哲子, 成瀬 光栄, 島津 章, 田上 哲也, 白神 幸太郎, 相川 幸生, 玉那覇 民子, 岡田 厚

    日本内分泌学会雑誌   93 ( 3 )   909 - 909   2017.12

     More details

    Language:Japanese  

  • Basedow病に対する放射性ヨウ素内用療法における副腎皮質ホルモン薬内服の抗TSH受容体抗体価への影響

    笹井 有美子, 兼子 大輝, 濱中 佳歩, 中谷 理恵子, 横本 真希, 馬越 洋宜, 立木 美香, 成瀬 光栄, 日下部 徹, 浅原 哲子, 島津 章, 田上 哲也

    日本内分泌学会雑誌   93 ( 4 )   1154 - 1154   2017.12

     More details

    Language:Japanese  

  • TRAb値とTSAb値に乖離を認めた高齢男性の甲状腺眼症の1例

    濱中 佳歩[廣嶋], 笹井 有美子, 兼子 大輝, 横本 真希, 馬越 洋宜, 立木 美香, 浅原 哲子, 成瀬 光栄, 濱 祥代, 田上 哲也

    日本内分泌学会雑誌   93 ( 4 )   1143 - 1143   2017.12

     More details

    Language:Japanese  

  • The Latest Developments of Functional Molecular Imaging in the Diagnosis of Primary Aldosteronism Reviewed

    Mitsuhide Naruse, Hironobu Umakoshi, Mika Tsuiki, Maki Yokomoto, Tetsuya Tagami, Akiyo Tanabe, Akira Shimatsu

    HORMONE AND METABOLIC RESEARCH   49 ( 12 )   929 - 935   2017.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Differentiation of unilateral from bilateral aldosterone hypersecretion is the essential step in the clinical practice of primary aldosteronism (PA). Although adrenal venous sampling (AVS) has been established as the most standard test recommended by the guideline, its invasive and technically difficult nature has facilitated the approach to develop non-invasive functioning imaging as an alternative test. Compared to the conventional adrenocortical scintigraphy with cholesterol derivatives as tracer, the first-generation imaging, both of (11) C-MTO/PET and (123) I-IMTO/SPECT/CT, the second-generation imaging, bind with high specificity and affinity to CYP11B enzymes and have advantages in shortening the time for obtaining specific images, reducing the radiation exposure to the patient, and resolution of the images. Because of very short half-life of (11) C-MTO, (123) I-IMTO has a potential for a wider application than (11) C-MTO. Sensitivity of identifying an adenoma smaller than 1cm in diameter is still a common limitation of these new functional imaging methods. The new functional imaging could be supplementary to AVS in lateralization of PA when the results of AVS are not conclusive. To be a substitute for AVS, however, it should fulfill various conditions including high selectivity and binding affinity to CYP11B2, high sensitivity in detecting small adenoma, high resolution image, reduction of radiation exposure, and general versatility. Considering the potential number of patients, cost-effectiveness of the subtype testing in the clinical practice of PA could be one of the issues of the medical expenses. Thus, development of a new non-invasive functional imaging will have a significant impact on the clinical practice of PA and hypertension.

    DOI: 10.1055/s-0043-120672

  • 原発性アルドステロン症、サブクリニカルクッシング症候群を合併したAdrenocortical oncocytomaの一例

    小笠原 辰樹, 兼子 大輝, 廣嶋 佳歩, 笹井 有美子, 横本 真希, 馬越 洋宜, 立木 美香, 田上 哲也, 伊藤 克弘, 奥野 博, 森吉 弘毅, 島津 章, 成瀬 光栄

    日本内分泌学会雑誌   93 ( 4 )   1461 - 1461   2017.12

     More details

    Language:Japanese  

  • Advanced glycation end product 3 (AGE3) increases apoptosis and the expression of sclerostin by stimulating THF-βexpression and sclerotsin in osteocyte-like MLO-Y4-A2 cells Reviewed

    Notsu M, Kanazawa I, Takeno A, Yokomoto-Umakoshi M, Tanaka KI, Yamaguchi T, Sugimoto T

    Calcif Tissue Int   100 ( 4 )   402 - 411   2017.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Advanced Glycation End Product 3 (AGE3) Increases Apoptosis and the Expression of Sclerostin by Stimulating TGF-beta Expression and Secretion in Osteocyte-Like MLO-Y4-A2 Cells
    Advanced glycation end products (AGEs) cause bone fragility due to deterioration in bone quality. We previously reported that AGE3 induced apoptosis and inhibited differentiation via increased transforming growth factor (TGF)-beta signaling in osteoblastic cells. Additionally, we demonstrated that AGE3 increased apoptosis and sclerostin expression and decreased receptor activator of nuclear factor-kappa B ligand (RANKL) expression in osteocyte-like cells. However, it remains unclear whether TGF-beta signaling is involved in the effects of AGEs on apoptosis and the expression of sclerostin and RANKL in osteocytes. Effects of AGE3 on apoptosis of mouse osteocyte-like MLO-Y4-A2 cells were examined by DNA fragmentation ELISA. Expression of TGF-beta, sclerostin, and RANKL was evaluated using real-time PCR, Western blotting, and ELISA kits. To block TGF-beta signaling, we used SD208, a TGF-beta type I receptor kinase inhibitor. AGE3 (200 A mu g/mL) significantly increased apoptosis and mRNA expression of Sost, the gene encoding sclerostin, and decreased Rankl mRNA expression in MLO-Y4-A2 cells. AGE3 significantly increased the expression of TGF-beta. Co-incubation of SD208 with AGE3 significantly rescued AGE3-induced apoptosis in a dose-dependent manner. Moreover, SD208 restored AGE3-increased mRNA and protein expression of sclerostin. In contrast, SD208 did not affect AGE3-decreased mRNA and protein expression of RANKL. These findings suggest that AGE3 increases apoptosis and sclerostin expression through increasing TGF-beta expression in osteocytes, and that AGE3 decreases RANKL expression independent of TGF-beta signaling.

    DOI: 10.1007/s00223-017-0243-x

  • Simvastatin rescues homocysteine-induced apoptosis of osteocytic MLO-Y4 cells by decreasing the expressions of NADPH oxidase 1 and 2 Reviewed

    Ayumu Takeno, Ippei Kanazawa, Ken-ichiro Tanaka, Masakazu Notsu, Maki Yokomoto-Umakoshi, Toshitsugu Sugimoto

    ENDOCRINE JOURNAL   63 ( 4 )   389 - 395   2016.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Clinical studies have shown that hyperhomocysteinemia is associated with bone fragility. Homocysteine (Hey) induces apoptosis of osteoblastic cell lineage by increasing oxidative stress, which may contribute to Hcy-induced bone fragility. Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, ameliorate oxidative stress by regulating oxidant and anti-oxidant enzymes. However, the effects of statins on Hcy-induced apoptosis of osteocytes are unknown. This study was thus aimed to investigate whether or not statins prevent Hcy-induced apoptosis of osteocytic MLO-Y4 cells and regulate NADPH oxidase (Nox) expression. TUNEL staining showed that 5 mM Hcy induced apoptosis of MLO-Y4 cells, and that co-incubation of 10(-9) or 10(-8) M simvastatin significantly suppressed the apoptotic effect. Moreover, we confirmed the beneficial effect of simvastatin against Hcy's apoptotic effect by using a DNA fragment ELISA assay. However, TUNEL staining showed no significant effects of pravastatin, a hydrophilic statin, on the Hcy-induced apoptosis. Real-time PCR showed that Hcy increased the mRNA expressions of Nox1 and Nox2, whereas simvastatin inhibited the stimulation of Nox1 and Nox2 expressions by Hcy. In contrast, neither Hcy nor simvastatin had any effect on Nox4 expression. These findings indicate that simvastatin prevents the detrimental effects of Hey on the apoptosis of osteocytes by regulating the expressions of Nox1. and Nox2, suggesting that statins may be beneficial for preventing Hey-induced osteocyte apoptosis and the resulting bone fragility.

  • Activation of AMP-activated protein kinase decreases receptor activator of NF-κB ligand expression and increases slcerostin expression by inhibiting the mevalonate pathway in osteocytic MLO-Y4 cells. Reviewed

    Yokomoto-Umakoshi M, Kanazawa I, Takeno A, Tanaka KI, Notsu M, Sugimoto T

    Biocem Biophys Res Commun   469 ( 4 )   791 - 796   2016.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Activation of AMP-activated protein kinase decreases receptor activator of NF-kappa B ligand expression and increases sclerostin expression by inhibiting the mevalonate pathway in osteocytic MLO-Y4 cells
    Background: AMP-activated protein kinase (AMPK) plays important roles in bone metabolism; however, little is known about its role in osteocytes. This study investigated the effects of AMPK activation on the expression of receptor activator of NF-kappa B ligand (RANKL) and sclerostin in osteocytes.
    Results: Real-time PCR showed that AMPK activation by 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) significantly decreased the expression of Rankl in a dose- and time-dependent manner and significantly increased the expression of Sost, the gene encoding sclerostin, in osteocytic MLO-Y4 cells. Western blotting confirmed that AICAR decreased RANKL protein levels and increased sclerostin levels. In addition, suppression of AMPK alpha 1 by siRNA significantly increased the expression of Rankl on 4 days after the transfection of siRNA, while Sost expression was not changed. Simvastatin, an inhibitor of HMG-CoA reductase, significantly decreased Rankl expression and increased Sost expression in MLO-Y4 cells. Supplementation with mevalonate or geranylgeranyl pyrophosphate, which are downstream metabolites of HMG-CoA reductase, significantly reversed the effects of AICAR.
    Conclusion: These findings indicated that AMPK regulated RANKL and sclerostin expression through the mevalonate pathway in osteocytes. (C) 2015 Elsevier Inc. All rights reserved.

    DOI: 10.1016/j.bbrc.2015.12.072

  • Activation of AMP-activated protein kinase protects against homocysteine-induced apoptosis of osteocytic MLO-Y4 cells by regulating the expressions of NADPH oxidase 1 (Nox1) and Nox2 Reviewed

    Ayumu Takeno, Ippei Kanazawa, Ken-ichiro Tanaka, Masakazu Notsu, Maki Yokomoto, Toru Yamaguchi, Toshitsugu Sugimoto

    BONE   77   135 - 141   2015.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Background: Elevated plasma homocysteine (Hcy) level is associated with the risk of osteoporotic fracture. While Hcy increases oxidative stress, AMP-activated protein kinase (AMPK) activation ameliorates it. This study aimed to investigate whether Hcy induces apoptosis of osteocytic MLO-Y4 cells through regulating expressions of oxidant and anti-oxidant enzymes and determine the effects of AMPK activation by 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR) and metformin on the Hcy-induced apoptosis of the cells.
    Results: DNA fragment ELISA and TUNEL staining assays showed that Hcy treatments (0.1-5.0 mM) induced apoptosis of MLO-Y4 cells in a dose-dependent manner. The detrimental effect of Hcy was partly but significantly reversed by an antioxidant (N-acetylcysteine) and NADPH oxidase (Nox) inhibitors (apocynin and diphenyleneiodonium). In addition, treatment with AICAR (0.05-0.1 mM) and metformin (10-100 mu M) ameliorated Hcy-induced apoptosis of the cells. The favorable effect of metformin on Hcy-induced apoptosis was completely canceled by an AMPK inhibitor Ara-A. Hcy increased the expression levels of Nox1 and Nox2, while it had no effects on the expressions of Nox4 or the anti-oxidant enzymes, superoxide dismutase 1 and 2. Hcy-induced increases in the expressions of Nox1 and Nox2 decreased significantly by treatments with AICAR.
    Conclusion: These findings suggest that Hcy induces apoptosis of osteocytes by increasing the expressions of Noxl and Nox2, and AMPK activation by AICAR and metformin effectively prevents the detrimental reactions. Thus, AMPK activation may be a potent therapeutic candidate for preventing Hcy-induced osteocyte apoptosis and the resulting bone fragility. (C) 2015 Elsevier Inc. All rights reserved.

    DOI: 10.1016/j.bone.2015.04.025

▼display all

Books

  • 副甲状腺・骨代謝疾患診療マニュアル

    横本 真希

    診断と治療社  2019.5 

     More details

    Language:Others  

Presentations

  • 骨粗鬆症・サルコペニアにおける副腎由来ホルモンの役割 Invited

    馬越真希

    第40回日本骨代謝学会学術集会(2022年度)  2022.7 

     More details

    Language:Others  

    Country:Other  

  • 副腎に由来するステロイドホルモンと骨・ミネラル代謝 Invited

    馬越真希

    教育講演18 第33回臨床内分泌代謝Update  2023.11 

     More details

    Language:Others  

    Country:Other  

  • 副腎由来ホルモンの多様性に基づいた骨粗鬆症進展機構の解明と医学応用 Invited

    馬越真希

    第40回日本骨代謝学会学術集会(2022年度)  2022.7 

     More details

    Language:Others  

    Country:Other  

  • Treat to targetを考慮した骨粗鬆症の治療戦略 Invited

    馬越真希

    第31回日本老年医学会九州地方会(2020年度)  2020.2 

     More details

    Language:Others  

    Country:Other  

MISC

  • 無症候性軽度コルチゾール自律産生(MACE)における分子病態の検討

    福元 多鶴, 馬越 洋宜, 小笠原 辰樹, 岩橋 徳英, 緒方 大聖, 兼子 大輝, 寺田 英李子, 馬越 真希, 松田 やよい, 坂本 竜一, 小川 誠司, 小川 佳宏

    日本内分泌学会雑誌   2022.4

     More details

    Language:Japanese  

  • 加齢性骨粗鬆症におけるDHEASの保護的役割

    馬越 真希, 馬越 洋宜, 岩橋 徳英, 松田 やよい, 兼子 大輝, 緒方 大聖, 福元 多鶴, 寺田 英李子, 中野 結衣, 坂本 竜一, 小川 佳宏

    日本内分泌学会雑誌   2022.4

     More details

    Language:Japanese  

  • コルチゾールのサルコペニアへの影響 メンデルランダム化研究

    勝原 俊亮, 馬越 真希, 馬越 洋宜, 松田 やよい, 岩橋 徳英, 兼子 大輝, 緒方 大聖, 福元 多鶴, 寺田 英李子, 坂本 竜一, 小川 佳宏

    日本内分泌学会雑誌   2022.4

     More details

    Language:Japanese  

  • アルドステロン産生腺腫によるコルチゾール合成

    緒方 大聖, 馬越 洋宜, 小笠原 辰樹, 福元 多鶴, 岩橋 徳英, 兼子 大輝, 寺田 英李子, 馬越 真希, 松田 やよい, 坂本 竜一, 小川 誠司, 小川 佳宏

    日本内分泌学会雑誌   2022.4

     More details

    Language:Japanese  

  • 機械学習を用いた原発性アルドステロン症の術後高血圧治癒予測

    兼子 大輝, 馬越 洋宜, 緒方 大聖, 和田 典男, 一城 貴政, 坂本 昌平, 渡邉 哲博, 馬越 真希, 松田 やよい, 坂本 竜一, 小川 佳宏

    日本内分泌学会雑誌   2022.3

     More details

    Language:Japanese  

  • 副腎由来ホルモンによる骨質制御機構に着目した新規骨粗鬆症診断モデルの開発

    馬越 真希, 和泉 自泰, 坂本 竜一

    大和証券ヘルス財団研究業績集   2022.3

     More details

    Language:Japanese  

    骨粗鬆症の早期診断法を開発するため、骨量正常にもかかわらず脆弱性骨折を引き起こす骨質劣化型骨粗鬆症に着目し、副腎由来ホルモンにおける骨粗鬆症への病態生理学的意義を検討した。副腎由来ホルモン過剰モデルであるヒト副腎腫瘍を対象とした観察研究、健常人を対象としたゲノムワイド関連研究を用いたメンデルランダム化研究、健常人の血液検体を対象とした網羅的ステロイドミクス解析を行った。その結果、副腎由来ホルモンは骨質制御に重要な役割を担っていることが明らかになった。さらに、生理的濃度の副腎由来ホルモンの変動も骨粗鬆症の進展に影響すること、健常人において副腎由来ホルモンに個人差を認めることも明らかになった。副腎由来ホルモンは有用な骨質サロゲート指標になり得ると考えられた。

  • コルチゾールのサルコペニアへの影響 メンデルランダム化研究

    勝原 俊亮, 馬越 真希, 馬越 洋宜, 松田 やよい, 岩橋 徳英, 兼子 大輝, 緒方 大聖, 福元 多鶴, 寺田 英李子, 坂本 竜一, 小川 佳宏

    日本内分泌学会雑誌   2022.3

     More details

    Language:Japanese  

  • 機械学習を用いた原発性アルドステロン症の術後高血圧治癒予測

    兼子 大輝, 馬越 洋宜, 和田 典男, 一城 貴政, 渡邉 哲博, 緒方 大聖, 馬越 真希, 松田 やよい, 坂本 竜一, 小川 佳宏

    日本内分泌学会雑誌   2021.12

     More details

    Language:Japanese  

  • 機械学習を用いた一般血液検査による原発性アルドステロン症のサブタイプ診断予測

    兼子 大輝, 馬越 洋宜, 緒方 大聖, 和田 典男, 岩橋 徳英, 福元 多鶴, 馬越 真希, 中野 結衣, 松田 やよい, 宮澤 崇, 坂本 竜一, 小川 佳宏

    日本内分泌学会雑誌   2021.4

     More details

    Language:Japanese  

  • FGF23と骨粗鬆症・心血管代謝疾患の因果関係の解明 メンデルランダム化研究

    馬越 真希, 馬越 洋宜, 宮澤 崇, 緒方 大聖, 坂本 竜一, 小川 佳宏

    日本内分泌学会雑誌   2021.4

     More details

    Language:Japanese  

  • 副腎静脈サンプリングにおける左副腎静脈内アルドステロン濃度勾配の意義

    緒方 大聖, 馬越 洋宜, 福元 多鶴, 松田 やよい, 馬越 真希, 永田 宙生, 和田 典男, 宮澤 崇, 坂本 竜一, 小川 佳宏

    日本内分泌学会雑誌   2021.1

     More details

    Language:Japanese  

  • 褐色細胞腫の骨粗鬆症進展における骨質劣化の役割

    馬越 真希, 馬越 洋宜, 坂本 竜一, 福元 多鶴, 緒方 大聖, 永田 宙生, 中野 結衣, 岩橋 徳英, 兼子 大輝, 溝口 範子, 服部 昭子, 宮澤 崇, 松田 やよい, 河手 久弥, 小川 佳宏

    日本内分泌学会雑誌   2020.10

     More details

    Language:Japanese  

  • 6年間の経過で病型診断が変化した原発性アルドステロン症の1例

    兼子 大輝, 立木 美香, 笹井 有美子, 濱中 佳歩, 嶋, 横本 真希, 馬越 洋宜, 日下部 徹, 浅原 哲子, 島津 章, 田上 哲也, 広川 侑奨, 奥野 博, 森吉 弘毅, 笹野 公伸, 成瀬 光栄

    日本内分泌学会雑誌   2018.4

     More details

    Language:Japanese  

    6年間の経過で病型診断が変化した原発性アルドステロン症の1例

  • 6年間の経過で病型診断が変化した原発性アルドステロン症の1例

    兼子 大輝, 立木 美香, 笹井 有美子, 濱中 佳歩, 嶋, 横本 真希, 馬越 洋宜, 日下部 徹, 浅原 哲子, 島津 章, 田上 哲也, 広川 侑奨, 奥野 博, 森吉 弘毅, 笹野 公伸, 成瀬 光栄

    日本内分泌学会雑誌   2018.4

     More details

    Language:Japanese  

    6年間の経過で病型診断が変化した原発性アルドステロン症の1例

  • TRAb値とTSAb値に乖離を認めた高齢男性の甲状腺眼症の1例

    濱中 佳歩, 廣嶋, 笹井 有美子, 兼子 大輝, 横本 真希, 馬越 洋宜, 立木 美香, 浅原 哲子, 成瀬 光栄, 島津 章, 濱 祥代, 田上 哲也

    日本内分泌学会雑誌   2018.4

     More details

    Language:Japanese  

    TRAb値とTSAb値に乖離を認めた高齢男性の甲状腺眼症の1例

  • 腫瘍細胞性と粘液性の特徴を有する副腎皮質腫瘍の1症例(A case of adrenocortical tumor with oncocytic and myxoid feature)

    小笠原 辰樹, 兼子 大輝, 濱中 佳歩, 笹井 有美子, 横本 真希, 馬越 洋宜, 立木 美香, 田上 哲也, 伊藤 克弘, 奥野 博, 森吉 弘毅, 島津 章, 山崎 有人, 笹野 公伸, 成瀬 光栄

    日本内分泌学会雑誌   2018.4

     More details

    Language:Japanese  

    腫瘍細胞性と粘液性の特徴を有する副腎皮質腫瘍の1症例(A case of adrenocortical tumor with oncocytic and myxoid feature)

  • 原発性アルドステロン症診療の標準化 コンセンサス・ステートメントについて

    成瀬 光栄, 立木 美香, 馬越 洋宣, 横本 真希, 笹井 由美子, 田上 哲也, 島津 章

    Medical Technology   2018.1

     More details

    Language:Japanese  

    原発性アルドステロン症診療の標準化 コンセンサス・ステートメントについて

  • 原発性アルドステロン症、サブクリニカルクッシング症候群を合併したAdrenocortical oncocytomaの一例

    小笠原 辰樹, 兼子 大輝, 廣嶋 佳歩, 笹井 有美子, 横本 真希, 馬越 洋宜, 立木 美香, 田上 哲也, 伊藤 克弘, 奥野 博, 森吉 弘毅, 島津 章, 成瀬 光栄

    日本内分泌学会雑誌   2017.12

     More details

    Language:Japanese  

    原発性アルドステロン症、サブクリニカルクッシング症候群を合併したAdrenocortical oncocytomaの一例

  • 【原発性アルドステロン症診療の進歩】 わが国の原発性アルドステロン症の診療に関するコンセンサス・ステートメント

    成瀬 光栄, 立木 美香, 馬越 洋宜, 横本 真希, 笹井 由美子, 田上 哲也, 島津 章

    血圧   2017.12

     More details

    Language:Japanese  

    【原発性アルドステロン症診療の進歩】 わが国の原発性アルドステロン症の診療に関するコンセンサス・ステートメント
    原発性アルドステロン症(PA)は高血圧における頻度が高く、治癒可能である一方、適切な診断・治療の遅れは治療抵抗性高血圧、種々の標的臓器障害の原因となることから、診療水準の向上と標準的医療の普及は重要な臨床的課題である。日本内分泌学会は日本高血圧学会、日本内分泌外科学会と協力して、診療の主要なクリニカルクエッションに対するクリニカルアンサーを、客観的なエビデンスに基づいたステートメントとして発表した。要点は(1)PA高頻度の高血圧患者での積極的なスクリーニング実施、(2)ARR>200とPAC>120pg/mlの場合にスクリーニング陽性と判断、(3)機能確認検査:カプトプリル試験、生食負荷試験、フロセミド立位試験、経口食塩負荷試験の中から少なくとも1種類の陽性を確認、(4)副腎腫瘍の確認のためthin sliceでの副腎SDCTを実施、(5)手術適応を考慮する場合は原則AVSを実施。ただし、35歳以下の典型的PAではAVSの省略も考慮、(6)局在判定の指標:ACTH負荷後Lateralized ratio(LR)>4かつContralateral ratio(CR)>1を推奨。結果が乖離した場合は総合判定、(7)片側性病変では副腎摘出術、両側性病変や手術不能な場合はMR拮抗薬を第一選択とする薬物治療、などである。しかしながら、わが国独自のエビデンスは不十分で、今後、現在進行中のAMED難治性疾患実用化研究JPASの結果を踏まえた改訂が必要と考えられる。(著者抄録)

  • 褐色細胞腫・パラガングリオーマの長期予後とQOL (特集 内分泌疾患の長期予後とQOL)

    横本 真希, 立木 美香, 馬越 洋宜, 小笠原 辰樹, 廣嶋 佳歩, 笹井 有美子, 田上 哲也, 島津 章, 成瀬 光栄

    ホルモンと臨床   2015.3

     More details

    Language:Japanese  

    Prognosis and QOL of pheochromocytoma/paraganglioma

  • Corsyntropin Stimulation Test with Low Dose Dexamethasone Suppression Is Useful for Subtype Classification in Primary Aldosteronism

    Hironobu Umakoshi, Tomikazu Fukuoka, Mayu Minamoto, Daisuke Utsunomiya, Maki Yokomoto, Kazuo Murakami, Shiori Kondo, Mitsuhide Naruse

    ENDOCRINE REVIEWS   2014.6

     More details

    Language:English  

▼display all

Professional Memberships

  • The Japan Endocrine Society

  • THE JAPANESE SOCIETY OF INTERNAL MEDICINE

  • THE JAPAN DIABETES SOCIETY

  • JAPANESE SOCIETY FOR BONE AND MINERAL RESEARCH

  • 日本骨粗鬆症学会

Research Projects

  • 加齢による副腎由来ホルモンの不均衡に基づいたフレイル診療戦略の構築

    2023 - 2025

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

      More details

    Authorship:Principal investigator  Grant type:Scientific research funding

  • ゲノム・メタボロームワイド関連解析を用いた副腎関連骨粗鬆症の病態解明

    2021

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

      More details

    Grant type:Scientific research funding

  • ステロイドプロファイリングを用いたサブクリニカルクッシング症候群における脆弱性骨折リスクの層別化

    2018 - 2019

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

      More details

    Authorship:Principal investigator  Grant type:Scientific research funding